Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Featured trial
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of

  • 222 views
  • 25 Mar, 2021
  • 1 location
Featured trial
  • 120 views
  • 25 Mar, 2021
  • 1 location
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an

mtor inhibitor
clear cell renal cell carcinoma
rad001
cancer
everolimus
  • 16 views
  • 24 Oct, 2022
  • 10 locations
Itacitinib + Everolimus in Hodgkin Lymphoma

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

refractory classical hodgkin lymphoma
platelet count
hysterectomy
positron emission tomography/computed tomography
gilbert's syndrome
  • 1 views
  • 04 Oct, 2022
  • 1 location
AERO: Adjuvant EveRolimus Outcomes in Laryngotracheal Stenosis

result in communication disability and high mortality rates due to the obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept study using the immunosuppressant drug

  • 0 views
  • 25 Oct, 2022
  • 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is

  • 24 views
  • 07 Nov, 2020
  • 1 location
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

tumor cells
triple-negative breast cancer
invasive breast cancer
primary tumor
cancer
  • 24 views
  • 14 Jun, 2022
  • 1 location
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward

  • 0 views
  • 02 May, 2022
  • 1 location
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.

  • 0 views
  • 04 Oct, 2022
  • 8 locations
SELUTION SLR™ 014 In-stent Restenosis

treatment with either the SELUTION SLR™ DEB or SOC to include contemporary DES (zotarolimus-eluting stents and everolimus-eluting stents only) or non-DEB BA. A maximum of 418 randomized subjects will be

aspirin
unstable angina
infarct
everolimus
angina pectoris
  • 0 views
  • 23 Apr, 2022
  • 2 locations